|
|
|
|
|||||
|
|
|
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best strong buy penny stocks to buy now. On July 25, ImmunityBio, Inc. (NASDAQ:IBRX) announced the preliminary financial results for the fiscal quarter ended June 30.
The company reported a notable 60% revenue growth to $26.4 million from Q1 2025, with year-to-date sales of ~$43 million. ANKTIVA underwent a 246% unit sales volume growth in H1 2025 compared to H2 2024.
ImmunityBio, Inc. (NASDAQ:IBRX) also reported $153.7 million in cash, cash equivalents, and marketable securities as of June 30.
ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage immunotherapy company that develops next-generation therapies to treat cancer and infectious diseases. Its immunotherapy platform activates the adaptive and innate immune systems to create long-term immunological memory.
While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
| Aug-05 | |
| Aug-05 | |
| Aug-05 | |
| Aug-04 | |
| Aug-01 | |
| Jul-31 | |
| Jul-25 | |
| Jul-25 | |
| Jul-23 | |
| Jul-09 | |
| Jul-07 | |
| Jul-07 | |
| Jul-02 | |
| Jun-24 | |
| Jun-12 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite